Fritextsökning
Innehållstyper
-
Marie Gårdmark: New incentives for orphan products on its way
"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...
-
Truly Labs AB
-
Webinar: Automate your processes
Free ZEISS webinar on January 30th, 2025.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, abou...
-
Webinar: Support Trial Patients Transitioning to the Commercial Space
Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.
-
One last chance to register for the premier metrology event in 2024
ZEISS QUALITY INNOVATION SUMMIT.
-
Joy at Egetis after positive CHMP opinion – ”The single most important milestone”
Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."
-
Marie Gårdmark: “What to expect from Trump’s second term?”
One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
Sweden is organising a large life science conference as part of the EU presidency
On 26-27 June, Sweden will host a European meeting on life science.
-
Several departures at the top at Nykode
Members of both the management and the board are leaving the Norwegian biotech company Nykode.
-
Are you curious about volume imaging for very large samples?
Exciting ZEISS Webinar!
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and wit...
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Among them are medicines for HIV, epilepsy, cancer and Parkinson’s, which may be withdrawn...
-
SupraCube - In life Science
Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...
-
Unmatched performance and flexibility in its class
The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...
-
Optimize Your Visibility
ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.
-
Tougher competition as the Novo Nordisk Foundation broadens its programme
Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...
-
The Oresund region aims at becoming Europe’s microbiome Mecca
The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.
-
He is zooming in on topical preparations
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting ap...
-
TFS Trial Form Support AB